Abstract:It is well accepted that the balance of immunity between effector and regulatory T cells determines the outcome of autoimmune and chronic inflammatory diseases. Concerning the topic of ‘Regulatory and Effector T Cells’ as published in this issue of Journal of Molecular Cell Biology, several investigators have provided important new information. T-helper 1 (Th1) and Th2 cells represent the classical type of Th or effector cells. However, recent studies have also identified several new cell subsets of Th cells, including IL-9-producing T (Th9), IL-17-producing T (Th17), IL-22-producing T (Th22), and T follicular helper (Tfh) cells, extending the Th cell structure. Given their crucial role in the pathogenesis of autoimmune and inflammatory diseases, Th17 cells have received much attention. They mainly express IL-17A, but co-express IL-17B, IL-17E (IL-25), IL-17F, and IL-22. IL-26 is produced by human but not mouse Th17 cells. IL-17A is significantly more potent in initiating signaling and causing autoimmune responses than other cytokines produced by these cells. The differentiation of mouse Th17 cells needs the combination of IL-6 and transforming growth factor-beta (TGF-b) (Bettelli et al., 2006), although IL-6or TGF-b-independent pathways may also contribute to Th17 cell differentiation. The role of TGF-b in human Th17 cell differentiation is still controversial. Of note, the IL-21 and IL-1 signal pathways seem to be important in initiating Th17 cell development. IL-21 and IL-23 are also known to sustain and expand Th17 cells. Dr Ryffel’s group provides an updated account of the differentiation and function of Th17 cells, particularly during lung injury and inflammatory disease. They demonstrated that lung injury or allergen exposure leads to NLPR3 activation, with formation of the NLPR3 inflammasome complex and caspase-1 activation resulting in mature IL-1b, which may elicit IL-17 production. Traditionally, asthma is elicited by Th2 cells. It is still unclear whether Th17 cells work independent or together with Th2 cells in the development of asthma. They suggest that Th17 cells promote asthma through modulation of Th2 cells. In fact, IL-17E or IL-25, another IL-17 member, can induce Th2 cytokines and promote allergy. It is also possible that IL-17 regulates allergic responses independent of Th2 cells but Th2 cells promote asthma through Th17 cells since IL-4 does regulate IL-17 levels. It has been widely accepted that Tregs are critically involved in immune tolerance and homeostasis. Although this concept was suggested in early 1970s, it was resuscitated in 1990s when thymus-derived CD4+CD25+ cells were identified as natural Tregs (nTregs) (Sakaguchi et al., 1995). While Foxp3 has been identified as a unique marker and functional transcription factor for these cells, studies on Tregs have been greatly accelerated. As Treg frequency and functional alterations are associated with many autoimmune diseases, the manipulation of these cells provides a promising treatment possibility for autoimmune diseases. In addition, use of Tregs may be valuable in the prevention of graft rejection of organ transplantation and graft-versus-host disease (GVHD). Dr Bluestone’s group further provides information on the potential use of these cells in the clinic. They reported that by 2011, three clinical trials have been undertaken to test the safety of Treg therapy in GVHD, and all have demonstrated promising safety and efficacy profiles. Compelling evidence from animal models and human patients demonstrates that tolerance to allogeneic transplant can be achieved by reconditioning the immune system, so that troublesome global immunosuppression can be minimized or completely stopped. They emphasize that a sound trial design should harness the tolerogenic potential of Tregs while minimizing risks. One potential risk with Treg therapy is that these cells can purportedly exhibit some measure of plasticity. Since little is known about the appropriate doses of Tregs in humans, initial trials should be safety-centered evaluating effect of increasing

GTS-21 Enhances Regulatory T Cell Development from T Cell Receptor-Activated Human CD4+ T Cells Exhibiting Varied Levels of CHRNA7 and CHRFAM7A Expression

GTS-21, an α7-nicotinic acetylcholine receptor agonist, modulates Th1 differentiation in CD4 + T cells from patients with rheumatoid arthritis.

Stimulation Of Alpha 7 Nicotinic Acetylcholine Receptor By Nicotine Increases Suppressive Capacity Of Naturally Occurring Cd4(+)Cd25(+) Regulatory T Cells In Mice In Vitro

Alpha 7 nicotinic acetylcholine receptors signaling boosts cell-cell interactions in macrophages effecting anti-inflammatory and organ protection

Lipopolysaccharide upregulates α7 acetylcholine receptors: stimulation with GTS-21 mitigates growth arrest of macrophages and improves survival in burned mice

GTS-21 alleviates murine collagen-induced arthritis through inhibition of peripheral monocyte trafficking into the synovium

Α7 Nicotinic Acetylcholine Receptor Mediates Lipopolysaccharide-Induced Inflammatory Response in the Mouse Macrophages

A Cellular MicroRNA Facilitates Regulatory T Lymphocyte Development by Targeting the FOXP3 Promoter TATA-Box Motif.

Chimeric antigen receptor‐modified human regulatory T cells that constitutively express IL‐10 maintain their phenotype and are potently suppressive

Mir-142-3p Regulates Autophagy by Targeting ATG16L1 in Thymic-Derived Regulatory T Cell (Ttreg).

Activation of Α7nachr by Nicotine Reduced the Th17 Response in CD4(+)T Lymphocytes.

Gene editing of gene to redirect regulatory T cells for adoptive T cell transfer

Antigen-specific transforming growth factor β-induced Treg cells, but not natural Treg cells, ameliorate autoimmune arthritis in mice by shifting the Th17/Treg cell balance from Th17 predominance to Treg cell predominance.

The human-specific nicotinic receptor subunit CHRFAM7A reduces α7 receptor function in human induced pluripotent stem cells-derived and transgenic mouse neurons

Emerging Topics and New Perspectives on Regulatory and Effector T Cells.

Characterization of Protective Human CD4CD25 FOXP3 Regulatory T Cells Generated with IL-2, TGF-β and Retinoic Acid.

High affinity chimeric antigen receptor signaling induces an inflammatory program in human regulatory T cells

DNA Methyltransferase Inhibitor Promotes Human CD4+CD25hFOXP3+ Regulatory T Lymphocyte Induction under Suboptimal TCR Stimulation

Enhanced Antitumor Responses of Tumor Antigen-Specific TCR T Cells Genetically Engineered to Produce IL7 and CCL19

Enhancement of Human Regulatory Γδ T Cells in Vitro Induced by Granulocyte Colony-Stimulating Factor

Activation of the α7nAChR by GTS-21 mitigates septic tubular cell injury and modulates macrophage infiltration